Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 3/20 | 0.32 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15292627 | 0.95 | ROCK2 (0.31) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL18806150 | 0.89 | ROCK2 (0.33) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL25089499 | 0.89 | — | — | |
| SCHEMBL18806174 | 0.85 | ROCK2 (0.32) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL22308379 | 0.85 | — | — | |
| SCHEMBL18806139 | 0.76 | — | — | |
| SCHEMBL18806135 | 0.76 | — | — | |
| SCHEMBL19120916 | 0.75 | — | — | |
| SCHEMBL19121494 | 0.75 | ROCK2 (0.34) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL19121218 | 0.75 | ROCK2 (0.32) | ROCK2ROCK1CDC42BPBCDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | ROCK2 704/4885ROCK1 2401/4885CDC42BPB 4160/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ROCK2 1134/4885ROCK1 1365/4885CDC42BPB 2704/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | ROCK2 704/4885ROCK1 2401/4885CDC42BPB 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.